the limits come first
CJC-1295 research: small studies and large gaps
The human work watched a few healthy adults only briefly. Blood tests changed, but no study found that anyone became healthier.
In rats, the blood-protein part kept the drug around longer
Peptide means that a small row of protein pieces makes CJC-1295. The study limits appear first, helping you decide how much trust the findings deserve.
The first work used rats and lab-grown cells rather than people. In rats, the blood-protein form produced a 4-fold greater hormone rise than the form without that grip [1].
After 72 hours, rat blood still held the longer form. Four altered pieces and the blood-protein grip each slowed removal [1].
These results explain the longer stay seen in later work. They cannot show you that anyone's health improved.
Small CJC-1295 studies found blood changes, not better health
The first CJC-1295 paper followed healthy adults aged 21 to 61, not patients seeking treatment. Each shot contained 30 or 60 micrograms per kilogram, a small amount set by body weight.
Growth hormone climbed 2- to 10-fold. IGF-1, a blood protein the liver makes after that hormone climbs, rose 1.5- to 3-fold for several days [2].
With repeated shots, IGF-1 remained higher than its opening reading for up to 28 days. Researchers put the time to clear half the CJC-1295 at 5.8-8.1 days [2].
A second paper watched healthy men aged 20 to 40. A 60 or 90 microgram-per-kilogram shot raised the lowest hormone reading about 7.5-fold [3].
Average growth hormone in the men rose about 46%, and IGF-1 rose about 45% after one week. The growth gland sent out hormone, then the liver made more IGF-1 [3].
A further paper followed 11 healthy young men. Several blood proteins shifted beside IGF-1, showing that IGF-1 moved with a wider blood response but no health gain for you [5].
The normal hormone bursts did not flatten out
A small CJC-1295 study checked men's hormones only briefly. While CJC-1295 remained, the hormone continued in natural waves instead of flattening [3].
The drug raised the level while leaving those natural bursts in place. Researchers don't know whether preserving that rhythm helps your health.
The next timing finding used mice alone. In those mice, 2 micrograms every 24 hours returned weight and body length to normal; gaps of 48 to 72 hours helped less [4].
CJC-1295 copies an order sent to the growth gland
CJC-1295 copies an order the body sends to its growth gland. A 2025 review groups it with sermorelin and tesamorelin, which copy that same order [10].
The drugs differ in how long they remain and whether they have approval. For you, those facts matter more than the shared lab label.
CJC-1295 vs sermorelin: what GHRH analog means
GHRH is the medical name for this hormone-release order. A GHRH analog is its lab-made copy; sermorelin is a briefer copy once used in tests and for some children [10].
Sermorelin lacks the blood-protein piece that helps the long form stay for days. Tesamorelin is approved for fat around the organs of certain patients living with HIV.
CJC-1295 has not been cleared for treating people [9][10]. Tesamorelin's approval can't make CJC-1295 safe or helpful.
The studies found hormone changes, not CJC-1295 benefits
CJC-1295 benefits have not been proved in people
The CJC-1295 studies in people were small and brief. Growth hormone stayed high for days, as did IGF-1, a growth-linked blood protein [2][3].
The usual hormone bursts also continued [3]. The work never checked strength, healing, fat loss, or longer life.
A mouse study gave the drug daily to mice bred without the usual growth order [4]. Those mice grew again, yet the finding cannot promise you a benefit.
No fair human study has tested those hoped-for gains. A Phase 2 study, an early benefit test, enrolled patients with HIV who also had fat packed around their organs, then ended for no clear public reason [9].
A seized doping product contained CJC-1295
The paper covered a seized sport-doping product, not a health study. When chemists tested that product, its main drug proved to be CJC-1295 [6].
The finding showed that the drug had entered a product outside formal studies [6]. No patient was named, and no health result was reported.
Sport rules forbid CJC-1295 year-round, and testing can detect it [9]. If you compete, that rule applies even while medical safety remains unsettled.